MIRD pamphlet No. 22 (Abridged): Radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy

George Sgouros, John C. Roeske, Michael R. McDevitt, Stig Palm, Barry J. Allen, Darrell R. Fisher, A. Bertrand Brill, Hong Song, Roger W. Howell, Gamal Akabani, Wesley E. Bolch, Ruby F. Meredith, Barry W. Wessels, Pat B. Zanzonico

Research output: Contribution to journalReview articlepeer-review

Abstract

The potential of α-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of α-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with α-particle emitters. Although α-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted α-particle emitter therapy and to provide guidance and recommendations for human α-particle emitter dosimetry.

Original languageEnglish (US)
Pages (from-to)311-328
Number of pages18
JournalJournal of Nuclear Medicine
Volume51
Issue number2
DOIs
StatePublished - Feb 1 2010

Keywords

  • Human α-particle emitter dosimetry
  • Targeted α-particle emitter therapy
  • α-particle emitters

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'MIRD pamphlet No. 22 (Abridged): Radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy'. Together they form a unique fingerprint.

Cite this